AU763183B2 - Methods to enhance and confine expression of genes - Google Patents

Methods to enhance and confine expression of genes Download PDF

Info

Publication number
AU763183B2
AU763183B2 AU56845/99A AU5684599A AU763183B2 AU 763183 B2 AU763183 B2 AU 763183B2 AU 56845/99 A AU56845/99 A AU 56845/99A AU 5684599 A AU5684599 A AU 5684599A AU 763183 B2 AU763183 B2 AU 763183B2
Authority
AU
Australia
Prior art keywords
promoter
tet
cassette
gal
dbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56845/99A
Other languages
English (en)
Other versions
AU5684599A (en
Inventor
Yuen Kai Fung
Charles Gomer
Anne T'ang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of AU5684599A publication Critical patent/AU5684599A/en
Application granted granted Critical
Publication of AU763183B2 publication Critical patent/AU763183B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU56845/99A 1998-08-18 1999-08-18 Methods to enhance and confine expression of genes Ceased AU763183B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9694798P 1998-08-18 1998-08-18
US60/096947 1998-08-18
PCT/US1999/019095 WO2000010612A1 (fr) 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes

Publications (2)

Publication Number Publication Date
AU5684599A AU5684599A (en) 2000-03-14
AU763183B2 true AU763183B2 (en) 2003-07-17

Family

ID=22259886

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56845/99A Ceased AU763183B2 (en) 1998-08-18 1999-08-18 Methods to enhance and confine expression of genes

Country Status (11)

Country Link
EP (1) EP1109582A4 (fr)
JP (1) JP2002523032A (fr)
KR (1) KR20020013463A (fr)
CN (1) CN1321093A (fr)
AU (1) AU763183B2 (fr)
CA (1) CA2340929A1 (fr)
IL (1) IL141473A0 (fr)
NZ (1) NZ509966A (fr)
RU (1) RU2226108C2 (fr)
WO (1) WO2000010612A1 (fr)
ZA (1) ZA200101207B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253379A1 (en) * 2002-08-09 2004-03-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
KR20030019282A (ko) * 2002-11-27 2003-03-06 김상태 βAPP의 C말단 pCT105 원격제어에 의한 치매발병 유도 세포주 개발
CA2800359A1 (fr) 2005-03-16 2006-09-28 Metabolix, Inc. Expression inductible chimiquement de voies biosynthetiques
CN102712933A (zh) * 2009-11-05 2012-10-03 西马生物医学计划公司 调控的表达系统
CN101892256B (zh) * 2010-01-27 2012-05-09 中国农业科学院北京畜牧兽医研究所 一种培育猪生长激素表达量增强的转基因动物的方法
CN103889440A (zh) 2011-08-08 2014-06-25 Cl昂科莱吉有限公司 用于癌症治疗和预防的涉及p62的方法和组合物
CN102786599B (zh) * 2012-08-01 2014-01-15 中国农业科学院作物科学研究所 水稻转录因子Os05g39950基因的应用
JP6498210B2 (ja) 2013-12-29 2019-04-10 チュアラボ オンコロジー, インコーポレーテッドCurelab Oncology, Inc. 炎症関連疾患の治療と予防のためのｐ６２／ｓｑｓｔｍ１に関する方法と組成物
CN105925609B (zh) * 2016-07-14 2019-01-08 中国医学科学院输血研究所 带有标记基因的Tet-on诱导过表达的重组载体及构建方法
CN110016464A (zh) * 2018-01-08 2019-07-16 张晋宇 用于筛选抗肿瘤物质的系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006864A2 (fr) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027021A1 (fr) * 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Vecteurs d'adenovirus interdependants et leurs procedes d'utilisation
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006864A2 (fr) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOMER ET AL. ABS OF 27TH ANNUAL MEETINGS OF THE AMERICAN SOCIETY FOR PHOTOBIOLOGY, VOL. 69, P.115, ABS.SAM D12 *

Also Published As

Publication number Publication date
NZ509966A (en) 2003-07-25
AU5684599A (en) 2000-03-14
IL141473A0 (en) 2002-03-10
CN1321093A (zh) 2001-11-07
CA2340929A1 (fr) 2000-03-02
KR20020013463A (ko) 2002-02-20
ZA200101207B (en) 2007-01-31
EP1109582A4 (fr) 2004-11-03
RU2226108C2 (ru) 2004-03-27
JP2002523032A (ja) 2002-07-30
WO2000010612A1 (fr) 2000-03-02
EP1109582A1 (fr) 2001-06-27

Similar Documents

Publication Publication Date Title
US20020065243A1 (en) Methods to enhance and confine expression of genes
Dong et al. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors
EP0751709B2 (fr) Utilisation de bcl-2 pour la fabrication de medicaments pour le traitement therapeutique et la prevention de maladies
Joki et al. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir
AU763714B2 (en) Gene therapy vectors and their use in antitumour therapy
AU763183B2 (en) Methods to enhance and confine expression of genes
Marples et al. Molecular approaches to chemo-radiotherapy
US20040234505A1 (en) Polynucleotide constructs and uses thereof
Lee et al. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy
Greco et al. Hypoxia-and radiation-activated Cre/loxP ‘molecular switch’vectors for gene therapy of cancer
WO2008112226A2 (fr) Constructions permettant l'immobilisation d'un gène basée sur la technique cre-lox, et leurs procédés d'utilisation
JP2004505647A (ja) 条件的阻害によるトランスジーンの発現をインビボで調節する方法
AU5318299A (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
Scott et al. Radiation and hypoxia inducible gene therapy systems
Liaudet-Coopman et al. A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth
US7267978B1 (en) Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression
MXPA01001776A (en) Methods to enhance and confine expression of genes
WO2001030799A1 (fr) Renforcement et confinement de l'expression genique en therapie anticancereuse
KR20000076115A (ko) 이종 유전자의 일시적이고 선택적인 발현을 위한 산화 스트레스를 생성하는 광역학적 치료요법
KR20160100010A (ko) 테트라사이클린에 의해 유전자 발현이 조절되는 재조합 벡터
Scanlon et al. Gene regulation in cancer gene therapy strategies
Senner et al. In vivo glioma model enabling regulated gene expression
WO2006017741A2 (fr) Promoteur iex-1 inductible par rayonnement
Konopka et al. Tet system in the brain: transgenic rats and lentiviral vectors approach
DE69823813T2 (de) Malignitätsunterdrückung unter verwendung von ribonukleotidreduktase r1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)